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Background
Cardiac involvement drives prognosis in amyloidosis.
ECV directly quantitates interstitial expansion and hence
myocardial amyloid burden. Native T1 is also elevated in
amyloid but reflects both cell and interstitial changes.
The combination gives insight into amyloid burden and
the myocyte response. Previously we have shown the uti-
lity of both techniques in AL amyloidosis. Here, we
explore the differences between the two main types of
amyloid, AL and ATTR types.
Methods
3 groups were studied: ATTR amyloid patients (n = 102;
age 72 ± 10); transthyretin mutations carriers (n = 8; age
47 ± 6); AL amyloid patients (n = 81; age 62 ± 10).
These were compared with 52 healthy volunteers and 43
patients with hypertrophic cardiomyopathy (HCM). All
underwent T1 mapping and ECV measurement. ATTR
patients and mutation carriers also underwent DPD
scintigraphy.
Results
ECV was massively elevated in ATTR patients compared
to HCM and healthy volunteers (0.58 ± 0.06 ms vs 0.37 ±
0.12 ms vs 0.27 ± 0.03 ms, both p > 0.0001). In estab-
lished cardiac ATTR amyloidosis, ECV elevation was
higher than AL amyloidosis (AL 0.53 ± 0.07 ms, p =
0.008) (Figure 1). Conversely, T1 was lower in TTR than
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Figure 1 ECV (left panel) and native myocardial T1 (right panel) in healthy volunteers, HCM, definite AL and definite ATTR
amyloidosis.
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AL amyloidosis (Figure 1). Diagnostic performance of
ECV was similar for AL and TTR (vs HCM: AL AUC
0.824 (0.745-0.902); TTR AUC 0.805 (95%CI 0.748-
0.862); both P < 0.0001). ECV tracked cardiac amyloid
burden as determined by DPD scintigraphy. ECV was not
elevated in mutation carriers (0.27 ± 0.02 ms) but was in
isolated DPD grade 1 (n = 8, 0.37 ± 0.09 ms, p = 0.001).
Correlations between ECV and other parameters showed
specific differences between AL and ATTR (Table 1).
Conclusions
ECV detects cardiac ATTR amyloid with similar diagnos-
tic performance and disease tracking to T1. The ECV is
higher in TTR - i.e. there is proportionately more amyloid
in TTR than AL hearts. However the native T1 is lower.
The discordance of ECV and T1 in AL and ATTR cardiac
amyloidosis highlights a possible difference in the myocyte
response, giving unique insight into the pathophysiology
of cardiac amyloidosis.
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Table 1
ATTR patients (R) AL patients
(R)
LV structure by MRI
LA areai, cm2/m2 0.695* 0.435*
LV systolic function by CMR 0.410* 0.258†
LVEF, % -0.523* 0.504*
SVi, ml/m2 -0.428* -0.428*
LV diastolic function by echo
E/E’ 0.512* 0.365*
E-deceleration time, ms -0.240 † -0.252†
6 minutes walking test -0.357* Ns
Biomarkers
NT-proBNP, pmol/L 0.789* 0.670*
Troponin T, pmol/L 0.681* 0.531*
ECG
PR, ms 0.472* ns
QRS, ms 0.281 * ns
ECG limb lead mean voltage -0.263 † -0.424 *
* P < 0.01 level; †P < 0.05;
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